Meta AnalysisID 1763
17α-羟孕酮己酸酯预防复发性早产：一项系统评价与Meta分析
CRD42017082190
Can 17α-hydroxyprogesterone caproate reduce the rate of recurrent preterm birth below 37 weeks of gestation with cervical length above and below 25mm? Can 17α-hydroxyprogesterone caproate reduce the rate of recurrent pr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1763
- Evidence Id
- 10321
- Core Evidence Id
- 10321
- Source Meta Analysis Id
- 1709
- Herb2 Meta Analysis Id
- HBMA001709
- Crd Id
- CRD42017082190
- Title
- 17α-hydroxyprogesterone caproate for the prevention of recurrent preterm birth: a systematic review and meta-analysis
- Review Question
- Can 17α-hydroxyprogesterone caproate reduce the rate of recurrent preterm birth below 37 weeks of gestation with cervical length above and below 25mm? Can 17α-hydroxyprogesterone caproate reduce the rate of recurrent preterm birth below 35 weeks of gestation with cervical length above or below than 25mm?
- Study Type Included
- Randomized controlled trials.
- Condition Being Studied
- Use of 17α-hydroxyprogesterone caproate for the reduction of preterm birth, defined as birth below 35 weeks and 37 weeks of gestation and cervical length above or below than 25mm.
- Participant
- Inclusion: randomized controlled trials of pregnant woman enrolled between 16 and 24+6 weeks of gestation with a history of at least one preterm delivery in any of their previous pregnancies between 20 and 36+6 weeks of gestation, and current treatment with 17α-hydroxyprogesterone caproate for the prevention of preterm birth starting before 24+6 weeks. Exclusion: studies with controls groups using vaginal progesterone. Studies with patients using cervical cerclage for prevention of preterm birth. Malformed fetuses, twin pregnancies.
- Animal
- Human Disease Modelled
- Intervention
- Pregnant woman with history of any previous preterm birth (between 20 and 36+6 weeks of gestation, regarding the cause of preterm delivery) enrolled for treatment with 17α-hydroxyprogesterone caproate before 24+6 weeks of gestation in current pregnancy.
- Comparator Control
- Pregnant woman with history of any previous preterm birth (between 20 and 36+6 weeks of gestation, regarding the cause of preterm delivery) enrolled for no treatment in current pregnancy.
- Main Outcome
- Risk of preterm birth (below 37 weeks of gestation) weighted by risk ratio, within the 17α-hydroxyprogesterone caproate and no treatment group no matter the cervical length at the time of enrolment. Measures of effect Pooled data will be evaluated by weighted risk ratio by inverse of variance.
- Outcome Measure
- Additional Outcome
- Risk of preterm birth (below 37 weeks of gestation) weighted by odds ratio, within the 17α-hydroxyprogesterone caproate and no treatment group in studies with cervical length <; 25 mm at the time of enrolment. Risk of preterm birth (below 37 weeks of gestation) weighted by risk ratio, within the 17α-hydroxyprogesterone caproate and no treatment group in studies with cervical length 25 mm at the time of enrolment. Risk of preterm birth (below 35 weeks of gestation) weighted by odds ratio, within the 17α-hydroxyprogesterone caproate and no treatment group no matter the cervical length at the time of enrolment. Risk of preterm birth (below 35 weeks of gestation) weighted by odds ratio, within the 17α-hydroxyprogesterone caproate and no treatment group in studies with cervical length <; 25 mm at the time of enrolment. Risk of preterm birth (below 35 weeks of gestation) weighted by odds ratio, within the 17α-hydroxyprogesterone caproate and no treatment group in studies with cervical length 25 mm at the time of enrolment. Measures of effect Pooled data will be evaluated by weighted odds ratio by inverse of variance.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- 17-alpha-Hydroxyprogesterone; Caproates; Humans; Premature Birth; hexanoic acid
- Contact
- Raigam Jafet Martinez Portilla [email protected]
- Organisational Affiliation
- BCNatal / Hospital Clinic de Barcelona www.medicinafetalbarcelona.org
- Funding Source
- Other Selection Criteria
- Final Publication
- Int J Gynaecol Obstet. 2019 Aug 11. doi: 10.1002/ijgo.12940. [Epub ahead of print]. https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.12940
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- Spain
- Review Stage
- Review Completed published
- First Submission Date
- 2017-11-23
- Registration Date
- 2017-12-19
- Anticipated Start Date
- 2017-11-07
- Anticipated Completion Date
- 2018-01-01
- Title Cn
- 17α-羟孕酮己酸酯预防复发性早产：一项系统评价与Meta分析
- Title En
- 17α-hydroxyprogesterone caproate for the prevention of recurrent preterm birth: a systematic review and meta-analysis
- Bilingual Status
- complete